From UK a small phase 1/2 clinical trial based on retinal gene therapy in patients with choroideremia. This is a X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1).
Cristiana Bernini
Aspirin halts growth of cranial tumors
A retrospective analysis of 600 patients with vestibular schwannoma at Massachusetts Eye and Ear (Harvard Medical School) suggests a therapeutic role of aspirin in inhibiting tumor growth.
What about the future?
Pharma World Magazine interviews Pietro Antonio Tataranni, Vice President Global Medical Operations Sanofi, on the future of the pharmaceutical research
Caterina Lazzarini
Each pharmaceutical researcher knows how finding new drugs is discouraging and how many diseases has had no pharmacological treatment yet. It seems that something has gone wrong in the last decades, but new hopes are arising from translational medicine.
A value sector
Outsourcing. It’s a new keyword in the modern industry that defines the contracting out of a business process to a third-party external to the Company. This approach is becoming more and more common among all the industries, pharmaceutical included
Tiziana Azzani
Outsourcing enables companies to optimize the timing and the production processes with positive effects on the cost and the quality of the finished product. «In Italy – declared Roberto Teruzzi, Chairman of the Contract Manufacturing Companies Group of Farmindustria, the Italian pharmaceutical industry association
Good as New
Bosch speeds up line delivery for Nuova Ompi with successful modification project
Nuova Ompi’s expertise in handling glass goes back more than 60 years. The company belongs to the Glass Division of the global Stevanato Group, a leading manufacturer of glass tubing containers for pharmaceutical applications.
A full-service partner for winning products
Interviewing Maurizio Catanese, General Manager at Humana Pharma International, a company specializing in the development and production of nutritional supplements, cosmetics and medical devices, with a modular and flexible full-service for all phases of development and production
Giovanni Bernuzzi
Founded in 1995, HPI (Humana Pharma International Spa) is structured in two divisions: Dietetic Division and Cosmetic Division, which develop and produce nutritional supplements, cosmetics and medical devices, with strong specialization in baby care and dermatologic cosmetics.
Keeping in touch with the outer world
Liquidweb is an Italian start-up specialized in the development of innovative assisted communication technologies to help locked-in patients to communicate simply by thinking
Giuliana Miglierini
Locked-in patients are people which, apparently, have completely lost their ability to communicate with the external world; they cannot use the sensitive organs, for example eyes to write using computer-assisted technologies, neither do any type of physical movement.
What in hot in the Healthcare industry
Based on a “2013 Search for Growth” survey, Frost&Sullivan’s insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and Beyond
Caterina Lucchini
Frost & Sullivan have still proposed the results of the big “2013 Search for Growth” survey which involved 1835 executives in more than 40 countries worldwide. Of responders, 56% work in large organization with over 1$ billion annual revenues. The predictions for the global Healthcare market identifies
Still attractive after all these up’s & down’s
A number of reports by such names as PriceWaterhouseCoopers and the India brand equity foundation (Ibef) have recently pointed out the Indian pharmaceutical market is slowing down also due to uncertainties which affect the national regulatory landscape; but it still offers opportunities
Roberto Carminati
Commentators and editors at The Hindu showed no doubt in stating that «the Indian pharmaceutical market isn’t going to be that rosy» and indeed the national scenario has recently shown some controversies that players in the drugs development and distribution arena will necessarily have to take into account.
Solid tumors are rocketing but industry growth is modest
A glance at neo-plastic phenomena in the Asia-Pacific macro-region displayed how such forms as pancreatic, ovarian, prostate and bladder cancers are on the rise. But analysts at Gbi Research show their pharmaceutical treatment market is not growing steadily enough, due to a series of reasons
Roberto Carminati
Recent figures from the London, Uk based multinational market insight company Gbi Research showed that the Asia-Pacific solid tumors treatment market is nowadays rising but that still, its growth rate is not enough to satisfy the real needs of such nations as Australia, China and India.
Newsstand
-
NCF International n.2 - 2025
-
NCF International n.1 - 2025
-
NCF International n.3 - 2024